List of Prezista drug patents
Prezista is owned by Janssen Prods.
Prezista contains Darunavir.
Prezista has a total of 4 drug patents out of which 0 drug patents have expired.
Prezista was authorised for market use on 23 June, 2006.
Prezista is available in tablet;oral dosage forms.
The generics of Prezista are possible to be released after 26 June, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(8 months from now) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(1 year, 2 months from now) | |
|
US7700645 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(4 years from now) | |
Drugs and Companies using DARUNAVIR ingredient
Market Authorisation Date: 23 June, 2006
Treatment: NA
Dosage: TABLET;ORAL
PREZISTA family patents
8
United States
6
European Union
4
Spain
3
Denmark
3
Cyprus
3
Portugal
3
Slovenia
2
Korea, Republic of
2
Australia
1
Hong Kong
1
AP
1
Poland
1
China
1
Brazil
1
Canada
1
EA
1
Norway
1
Japan
1
New Zealand
1
Croatia
1
Mexico
1
South Africa
1
Lithuania
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic